XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) and Burning Rock Biotech (NASDAQ:BNR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
XTL Biopharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
Profitability
This table compares XTL Biopharmaceuticals and Burning Rock Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XTL Biopharmaceuticals | N/A | N/A | N/A |
| Burning Rock Biotech | -13.60% | -12.98% | -8.59% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XTL Biopharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Burning Rock Biotech | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares XTL Biopharmaceuticals and Burning Rock Biotech”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XTL Biopharmaceuticals | $450,000.00 | 9.93 | -$6.97 million | ($0.64) | -2.95 |
| Burning Rock Biotech | $77.16 million | 1.99 | -$7.92 million | ($0.87) | -16.79 |
XTL Biopharmaceuticals has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than XTL Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
XTL Biopharmaceuticals beats Burning Rock Biotech on 7 of the 10 factors compared between the two stocks.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
About Burning Rock Biotech
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
